Regen BioPharma (RGBP) 10-Q 5 Aug 21 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2020	May 14, 2021
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	0001589150
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity's Reporting Status Current?	No
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,746,423,788
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Entity Interactive Data Current	No
Entity Incorporation, State or Country Code	NV
Entity File Number	333-191725

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
CURRENT ASSETS
Cash	$ 0	$ 7,855
Accounts Receivable, Related Party	75,466	71,186
Prepaid Expenses	40	76
Total Current Assets	75,506	79,117
OTHER ASSETS
Investment Securities	19,969	19,969
Total Other Assets	19,969	19,969
TOTAL ASSETS	95,475	99,087
Current Liabilities:
Accounts payable	107,430	92,000
Notes Payable	62,127	88,627
Accrued payroll taxes	4,241	4,241
Accrued Interest	754,951	525,335
Accrued Rent	23,548	5,000
Accrued Payroll	1,148,819	972,158
Other Accrued Expenses	41,423	41,423
Bank Overdraft	854
Due to Investor	20,000	20,000
Derivative Liability	4,020,486	7,200,528
Convertible Notes Payable Less unamortized discount	2,454,604	2,051,537
Unearned Income		0
Convertible Notes Payable, Related Parties Less unamortized discount	16,061	2,056
Total Current Liabilities	8,654,546	11,002,904
Long Term Liabilities:
Convertible Notes Payable less unamortized discount	0	0
Convertible Notes Payable, Related Parties Less unamortized discount	0	4,978
Total Long Term Liabilities	0	4,978
Total Liabilities	8,654,546	11,007,882
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 4,800,000,000 authorized and 1,605,000,246 issued and outstanding as of June 30, 2020 and 4,800,000,000 authorized and 600,001,406 shares issued and outstanding September 30, 2019	160,498	59,998
Additional Paid in capital	8,298,393	8,261,993
Contributed Capital	728,791	728,658
Retained Earnings (Deficit)	(17,786,519)	(19,998,086)
Total Stockholders' Equity (Deficit)	(8,559,071)	(10,908,795)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	95,475	99,087
Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	34,838	34,838
Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	5	5
Series M Preferred Stock [Member]
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	$ 4,400	$ 3,800

CONSOLIDATED CONDENSED BALANC_2

CONSOLIDATED CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Sep. 30, 2019
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	4,800,000,000	4,800,000,000
Common stock, shares issued	160,500,246	600,001,406
Common stock, shares outstanding	160,500,246	600,001,406
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series A Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares issued	348,376,230	348,376,230
Preferred stock, shares outstanding	348,376,230	348,376,230
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued	50,000	50,000
Preferred stock, shares outstanding	50,000	50,000
Series M Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares issued	44,000,000	38,000,000
Preferred stock, shares outstanding	44,000,000	38,000,000

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
REVENUES
Revenues, Related Party	$ 27,425	$ 27,425	$ 54,849	$ 54,849
COST AND EXPENSES
Research and Development	2,823	1,346	10,342	7,940
General and Administrative	57,887	126,514	162,245	285,416
Consulting and Professional Fees	2,500	115,357	37,786	161,120
Rent	3,548	15,000	18,548	30,000
Total Costs and Expenses	66,758	258,217	228,921	484,476
OPERATING INCOME (LOSS)	(39,334)	(230,793)	(174,072)	(429,627)
OTHER INCOME & (EXPENSES)
Interest Income	0	0	0	1,302
Other Income	0	0		0
Dividend Income	0	0	0	0
Loss on Sale of Securities	0	0	0	(57,697)
Unrealized (Gain) Loss on Investment Securities	0	(62,363)	0	(59,147)
Interest Expense	(82,022)	(68,117)	(170,657)	(141,941)
Refunds of amounts previously paid		115		115
Interest Expense attributable to Amortization of Discount	(188,465)	(301,830)	(388,820)	(678,100)
Gain (Loss) on Early Extinguishment Convertible Debt	0	0	0	0
Bad Debt Expense	0	(118,121)	0	(118,121)
Other Than Temporary Impairment Recognized	0	0	0	0
Derivative Income (Expense)	(3,767,325)	447,931	(260,828)	1,395,095
TOTAL OTHER INCOME (EXPENSE)	(4,037,812)	(102,385)	(820,305)	341,507
NET INCOME (LOSS)	(4,077,145)	(333,177)	(994,377)	(88,120)
Less:Net (Income) Loss attributable to KCL, Therapeutics, Inc.	0	(2,500)	0	(2,500)
NET INCOME (LOSS) attributable to common shareholders	$ 0	$ (335,677)	$ 0	$ (90,620)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ 0.0026	$ 0.0011	$ (0.0005)	$ (0.0004)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	1,575,654,650	295,684,600	1,810,483,239	255,155,894

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDER'S EQUITY (Unaudited) - USD ($)	Series A Preferred Stock	Series AA Preferred Stock	Common Stock	Series M Preferred stock	Additional Paid-In Capital	Retained Earnings	Contributed Capital	Other Comprehensive Income (Loss)	Noncontrolling Interest	Total
Beginning balance, Shares at Sep. 30, 2018	140,434,496	50,000	180,315,107	38,000,000
Beginning balance, Amount at Sep. 30, 2018	$ 14,044	$ 5	$ 18,030	$ 3,800	$ 7,517,888	$ (17,457,044)	$ 728,658	$ 52,948	$ 0	$ (9,121,671)
Shares issued for debt, Shares			5,128,205
Shares issued for debt, Amount			$ 513		29,487					30,000
Shares issued for debt, Shares			8,961,988
Shares issued for debt, Amount			$ 896		29,754					30,650
Shares issued for debt, Shares			2,019,140
Shares issued for debt, Amount			$ 202		7,410					7,612
Shares issued for debt, Shares			3,015,618
Shares issued for debt, Amount			$ 302		11,066					11,368
Shares issued for debt, Shares			7,100,591
Shares issued for debt, Amount			$ 710		29,290					30,000
Shares issued for debt, Shares	3,656,020
Shares issued for debt, Amount	$ 366				5,099					5,465
Shares issued for debt, Shares			29,033,181
Shares issued for debt, Amount			$ 2,903		47,813					50,716
Shares issued for expenses, Shares			286,232
Shares issued for expenses, Amount			$ 29		471					500
Shares issued for debt, Shares			5,184,674
Shares issued for debt, Amount			$ 518		9,929					10,447
Shares issued for debt, Shares			10,382,717
Shares issued for debt, Amount			$ 1,038		7,372					8,410
Shares issued for expenses, Shares			617,283
Shares issued for expenses, Amount			$ 62		438					500
Derecognition of Accumulated Other Comprehensive Income						52,948		(52,948)		0
Adjustment for noncontrolling Interest KCL Therapeutics, Inc.						29,186				29,186
Net Income (loss)						245,057				245,057
Ending balance, Shares at Dec. 31, 2018	144,090,516	50,000	252,044,737	38,000,000
Ending balance, Amount at Dec. 31, 2018	$ 14,409	$ 5	$ 25,203	$ 3,800	7,696,017	(17,129,853)	728,658	0	0	(8,661,761)
Shares issued for debt, Shares			10,585,123
Shares issued for debt, Amount			$ 1,059		12,692					13,751
Shares issued for services, Shares	10,000,000
Shares issued for services, Amount	$ 1,000				48,000					49,000
Shares issued for debt, Shares			5,774,947
Shares issued for debt, Amount			$ 577		6,555					7,132
Shares issued for debt, Shares			12,222,690
Shares issued for debt, Amount			$ 1,222		5,744					6,966
Shares issued for expenses, Shares			877,310
Shares issued for expenses, Amount			$ 88		412					500
Shares issued for debt, Shares			10,473,668
Shares issued for debt, Amount			$ 1,047		11,887					12,934
Shares issued for debt, Shares			13,821,193
Shares issued for debt, Amount			$ 1,382		14,374					15,756
Shares issued for debt, Shares			13,790,783
Shares issued for debt, Amount			$ 1,379		18,341					19,720
Shares issued for debt, Shares			8,004,463
Shares issued for debt, Amount			$ 800		7,844					8,644
Shares issued for expenses, Shares			694,508
Shares issued for expenses, Amount			$ 69		431					500
Shares issued for debt, Shares			14,305,492
Shares issued for debt, Amount			$ 1,431		8,868					10,299
Shares issued for expenses, Shares			833,449
Shares issued for expenses, Amount			$ 83		417					500
Shares issued for debt, Shares			27,377,166
Shares issued for debt, Amount			$ 2,738		19,766					22,504
Shares issued for debt, Shares			6,309,524
Shares issued for debt, Amount			$ 631		4,669					5,300
Shares of subsidiary issued for services					441					441
Adjustment for noncontrolling Interest KCL Therapeutics, Inc.					(2,934)				2,934	0
Net Income (loss)						(333,177)				(333,177)
Ending balance, Shares at Mar. 31, 2019	154,090,516	50,000	377,115,053	38,000,000
Ending balance, Amount at Mar. 31, 2019	$ 15,409	$ 5	$ 37,710	$ 3,800	7,853,523	(17,463,031)	728,658	0	0	(8,820,991)
Beginning balance, Shares at Sep. 30, 2019	348,376,230	50,000	600,001,406	38,000,000
Beginning balance, Amount at Sep. 30, 2019	$ 34,838	$ 5	$ 59,998	$ 3,800	8,261,993	(19,998,086)	728,658			(10,908,795)
Shares issued for debt, Shares			15,100,608
Shares issued for debt, Amount			$ 1,510		3,397					4,907
Shares issued for services, Shares				6,000,000
Shares issued for services, Amount				$ 600						600
Shares issued for interest, Shares			4,376,007
Shares issued for interest, Amount			$ 438		984					1,422
Shares issued for fees, Shares			5,555,556
Shares issued for fees, Amount			$ 556		(56)					500
Shares issued for interest, Shares			4,217,031
Shares issued for interest, Amount			$ 422		1,096					1,518
Shares issued for Interest, Shares			30,946,444
Shares issued for Interest, Amount			$ 3,095		(310)					2,785
Shares issued for debt, Shares			20,834,497
Shares issued for debt, Amount			$ 2,083		7,917					10,000
Shares issued for interest, Shares			3,418,941
Shares issued for interest, Amount			$ 342		1,299					1,641
Shares issued for debt, Shares			25,002,163
Shares issued for debt, Amount			$ 2,500		6,500					9,000
Shares issued for interest, Shares			8,745,416
Shares issued for interest, Amount			$ 875		1,750					2,625
Shares issued for fees, Shares			5,548,380
Shares issued for fees, Amount			$ 555		(55)					500
Shares issued for debt, Shares			19,254,584
Shares issued for debt, Amount			$ 1,925		3,850					5,775
Shares issued for interest, Shares			36,500,000
Shares issued for interest, Amount			$ 3,056		7,944					11,000
Shares issued for interest, Shares			36,500,000
Shares issued for interest, Amount			$ 3,650		2,920					6,570
Shares issued for debt, Shares			31,251,177
Shares issued for debt, Amount			$ 3,125		3,625					6,750
Shares issued for interest, Shares			4,393,684
Shares issued for interest, Amount			$ 439		510					949
Shares issued for debt, Shares			30,558,094
Shares issued for debt, Amount			$ 3,056		2,444					5,500
Shares issued for interest, Shares			5,556,017
Shares issued for interest, Amount			$ 556		444					1,000
Shares issued for debt, Shares			31,234,276
Shares issued for debt, Amount			$ 3,123		2,967					6,090
Shares issued for interest, Shares			5,308,288
Shares issued for interest, Amount			$ 531		504					1,035
Shares issued for debt, Shares			41,922,222
Shares issued for debt, Amount			$ 4,192		3,354					7,546
Shares issued for debt, Shares			10,064,761
Shares issued for debt, Amount			$ 1,006		(99)					907
Shares issued for interest, Shares			26,310,416
Shares issued for interest, Amount			$ 2,631		(260)					2,371
Shares issued for debt, Shares			49,729,272
Shares issued for debt, Amount			$ 4,973		905					5,878
Common Shares issued for debt, Shares			37,777,157
Common Shares issued for debt, Amount			$ 3,778		(1,512)					2,266
Shares issued for Fees, Shares			8,335,648
Shares issued for Fees, amount			$ 834		(334)					500
Shares issued for debt, Shares			52,200,000
Shares issued for debt, Amount			$ 5,220		(2,088)					3,132
Shares issued for debt, Shares			42,081,411
Shares issued for debt, Amount			$ 4,208		1,262					5,470
Shares issued for interest, Shares			7,677,742
Shares issued for interest, Amount			$ 768		230					998
Shares issued for debt, Shares			41,433,258
Shares issued for debt, Amount			$ 4,143		3,314					7,457
Shares issued for interest, Shares			566,742
Shares issued for interest, Amount			$ 57		45					102
Shares issued for debt, Shares			50,462,834
Shares issued for debt, Amount			$ 5,046		(1,766)					3,280
Shares issued for interest, Shares			9,477,166
Shares issued for interest, Amount			$ 948		(332)					616
Shares issued for debt, Shares			59,900,000
Shares issued for debt, Amount			$ 5,990		(2,396)					3,594
Shares issued for debt, Shares			31,421,505
Shares issued for debt, Amount			$ 3,142		(2,200)					942
Shares issued for interest, Shares			11,808,081
Shares issued for interest, Amount			$ 1,181		(827)					354
Shares issued for Fees, Shares			16,678,081
Shares issued for Fees, amount			$ 1,668		(1,168)					500
Shares issued for interest, Shares			6,101,694
Shares issued for Interest, amount			$ 610		(244)					366
Capital contribution							133			133
Net Income (loss)						3,082,768				3,083,375
Ending balance, Shares at Dec. 31, 2019	348,376,230	50,000	1,422,306,114	44,000,000
Ending balance, Amount at Dec. 31, 2019	$ 34,838	$ 5	$ 142,228	$ 4,400	8,305,609	(16,915,318)	728,791			(7,699,447)
Shares issued for debt, Shares			69,685,185
Shares issued for debt, Amount			$ 6,969		(3,206)					3,763
Shares issued for interest, Shares			17,480,000
Shares issued for interest, Amount			$ 1,748		(1,224)					524
Shares issued for fees, Shares			16,666,667
Shares issued for fees, Amount			$ 1,667		(1,167)					500
Shares issued for debt, Shares			36,826,333
Shares issued for debt, Amount			$ 3,683		(2,578)					1,105
Shares issued for interest, Shares			18,615,919
Shares issued for interest, Amount			$ 1,862		(1,304)					558
Shares issued for debt, Shares			6,739,096
Shares issued for debt, Amount			$ 674		(472)					202
Shares issued for fees, Shares			16,680,931
Shares issued for fees, Amount			$ 1,668		(1,168)					500
Net Income (loss)						(4,077,145)				(4,077,145)
Ending balance, Shares at Mar. 31, 2020	348,376,230	50,000	1,605,000,246	44,000,000
Ending balance, Amount at Mar. 31, 2020	$ 34,838	$ 5	$ 160,498	$ 4,400	$ 8,294,491	$ (20,992,464)	$ 728,791			$ (8,559,071)

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ (994,377)	$ (88,120)
Adjustments to reconcile net Income to net cash
Preferred Stock issued to Consultants	600	0
Common Stock issued to consultants	0	49,000
Common Stock issued for interest	0	0
Preferred Stock Issued For Interest	0	0
Subsidiary Stock issued to consultants	0	46
Subsidiary Stock issued as compensation	0	294
Common Stock issued for Expenses	3,000	2,500
Increase (Decrease) in Interest expense attributable to amortization of Discount	388,820	678,100
(Gain) Loss on Sale of Investment Securities		57,697
Increase(Decrease) in (Gain)/Loss on early extinguishment of debt	0	0
Increase (Decrease) in Recognition of Other than Temporary Impairment	0	0
Unrealized (Gain) Loss on Investment Securities	0	59,147
Increase (Decrease) in Accounts Payable	12,641	(1,860)
Increase(Decrease) in Bank Overdraft	0	0
increase (Decrease) Unearned Income	0	(38,814)
(Increase) Decrease in Accounts Receivable	21,051	(16,035)
Increase (Decrease) in Accrued Expenses	325,530	280,912
(Increase) Decrease in Prepaid Expenses	24	13,259
Increase(Decrease) in Contributed Capital	133	0
Increase in Derivative Expense	260,828	(1,395,095)
(Increase) Decrease in Interest Receivable	0	(1,303)
(Increase) Decrease in Notes Receivable	0	4,551
Increase(Decrease) in Bad Debt Expense	0	118,121
Increase(Decrease) in Bank Overdraft	395	63
Net Cash Provided by (Used in) Operating Activities	18,645	(277,537)
Cash Flows from Investment Activities
Increase(Decrease) in Sale of Investment Securities	0	49,858
Dividend Income	0	0
Net Cash Provided By Investment Activities	0	49,858
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	0	0
Preferred Stock issued for Cash	0	0
Increase (Decrease) in Notes Payable	(26,500)	8,500
Increase in Convertible Notes Payable	0	226,250
Increase in Due to Investor	0	0
Net Cash Provided by (Used in) Financing Activities	(26,500)	234,750
Net Increase (Decrease) in Cash	(7,855)	7,071
Cash at Beginning of Period	7,855	8,019
Cash at End of Period	0	15,090
Supplemental Disclosure of Noncash Investing and Financing Activities:
Common Shares Issued for Debt	111,133	302,032
Preferred Shares Issued for Debt	0	5,000
Cash Paid for Interest	0	11,520
Common shares Issued for Interest	18,864	28,898
Preferred Shares issued for Interest	$ 0	$ 465

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31,2020 utilized the following inputs: Risk Free Interest Rate 1.75 % Expected Term – 0.41 Yrs Expected Volatility 273 – 312. % Expected Dividends C. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2020 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. D. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. E. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2020 and 2019. F. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. G. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. H. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Mar. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Going Concern

Going Concern	6 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $20,992,464 during the period from April 24, 2012 (inception) through March 31,2020. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise.

Notes Payable, Related Party

Notes Payable, Related Party	6 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Notes Payable Related Party	NOTE 4. NOTES PAYABLE, RELATED PARTY As of March 31, 2020 David Koos $ 227 BST Partners 61,900 Total: $ 62,127 11 $227 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum. On October 2, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $6,000 to the Company. The loan bears simple interest at 10% and is due and payable October 2, 2020. On October 4, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $2,300 to the Company. The loan bears simple interest at 10% and is due and payable October 4, 2020. On October 24, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $7,400 to the Company. The loan bears simple interest at 10% and is due and payable October 24, 2020. On October 25, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $1,000 to the Company. The loan bears simple interest at 10% and is due and payable October 25, 2020. On October 31, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $2,000 to the Company. The loan bears simple interest at 10% and is due and payable October 31, 2020. On November 6, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $1,500 to the Company. The loan bears simple interest at 10% and is due and payable November 6, 2020. On November 8, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $6,000 to the Company. The loan bears simple interest at 10% and is due and payable November 8, 2020. On November 15, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $2,000 to the Company. The loan bears simple interest at 10% and is due and payable November 15, 2020. On November 26, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $2,100 to the Company. The loan bears simple interest at 10% and is due and payable November 26, 2020. On December 2, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $1,000 to the Company. The loan bears simple interest at 10% and is due and payable December 2, 2020. On December 17, 2019 BST Partners, an entity controlled by the Company’s CEO loaned $1,300 to the Company. The loan bears simple interest at 10% and is due and payable December 18, 2020. On January 2, 2020 BST Partners, an entity controlled by the Company’s CEO loaned $1,400 to the Company. The loan bears simple interest at 10% and is due and payable January 2, 2021. On January 10, 2020 BST Partners, an entity controlled by the Company’s CEO loaned $2,500 to the Company. The loan bears simple interest at 10% and is due and payable January 10, 2021 On January 16, 2020 BST Partners, an entity controlled by the Company’s CEO loaned $1,400 to the Company. The loan bears simple interest at 10% and is due and payable January 16, 2021 During the year ended September 30, 2020 David Koos served as the Company’s Chairman and CEO until January 22,2020. On March 23, 2021 David R. Koos was appointed Chairman and Sole Director of Regen Biopharma, Inc. On March 23, 2021 David R. Koos was appointed Chief Executive Officer, President, Secretary and Treasurer of Regen Biopharma, Inc. On March 23, 2021 David R. Koos was appointed Chairman and Sole Director of KCL Therapeutics, Inc. On March 23, 2021 David R. Koos was appointed Chief Executive Officer, President, Secretary and Treasurer of KCL Therapeutics, Inc.

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property. The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $ 0. As of March 31, 2020 $100,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2020 is $0. On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $0. As of March 31, 2020 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2020 is $0. On September 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $ 0. As of March 31, 2020 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2020 is 0. On September 20, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $ 0. As of March 31, 2020 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2020 is 0. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31 30, 2020 the unamortized discount on the convertible note outstanding is $0. As of March 31, 2020 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2020 is 0. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $ 0 As of March 31, 2020 $50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $0. As of March 31, 2020 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2020 is 0. On December 22, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $40,000 for consideration consisting of $40,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.01 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $40,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $ 0. As of March 31, 2020 $40,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of March 31, 2020 is 0. On March 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $75,000 for consideration consisting of $75,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 1, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31 , 2020 $75,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $300,000 was recognized by the Company as of March 31, 2020. The issuance of the Note amounted in a discount of $75,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $0. On March 9, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 9, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30, 2020 $25,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $100,000 was recognized by the Company as of March 31, 2020. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $0. March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31, 2020 $50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,000 was recognized by the Company as of March 31, 2020. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $0. On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31,2020 $50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,000 was recognized by the Company as of March 31, 2020. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of March 31, 2020 the unamortized discount on the convertible note outstanding is $0 On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of March 31, 2020 $25,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $100,000 was recognized by the Company as of March 31, 2020. The issuance of the Note amounte

Related Party Transactions

Related Party Transactions	6 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 6. RELATED PARTY TRANSACTIONS On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto. On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby: 1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement. 2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement. 3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement. No actions were taken by any of the parties to enforce the terms of the Agreement. On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be: a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto. Zander and Regen are under common control. On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s then Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.01 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.01 per share. In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of March 31, 2020 $11,500 of the principal amount of the Note remains outstanding. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of March 31, 2020, $10,000 of the principal amount of the Note remains outstanding. As of March 31, 2020 the Company is indebted to David R. Koos the Compoany’s sole officer and director in the amount of $227. $227 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. As of March 31, 2020 the Company is indebted to BST Partners, an entity controlled by the Company’s Chairman and CEO, in the amount of $61,900.

Accounts Receivable, Related Pa

Accounts Receivable, Related Party	6 Months Ended
	Mar. 31, 2020
Credit Loss [Abstract]
Accounts Receivable, Related Party	NOTE 7. ACCOUNTS RECEIVABLE, RELATED PARTY Accounts Receivable due from Related Party as of March 31, 2020 consists solely of amounts earned by the Company not yet paid resulting from the Company’s license agreement with KCL Therapeutics ( See Note 6).

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 8. COMMITMENTS AND CONTINGENCIES On December 13, 2019 a complaint was filed in the Superior Court of California, County of San Diego against Regen Biopharma, Inc. (“Company”) , the Company’s Chairman, Zander Therapeutics Inc (“Zander”), and Does 1-50 by ChemDiv, Inc. (“Plaintiff”) alleging Breach of Contract, Unfair Business Practices under the California Business and Professions Code, and Bad Faith Denial of a Contract ( alleged solely against the Company and DOE defendants) stemming from contract research work performed by the Plaintiff for the Company and contract research performed by the Plaintiff for Zander. The Plaintiff is also seeking a declaration from the court that the Plaintiff retains full and complete ownership, title, use, and all rights without any limits to the work, tangible property, intellectual property, and any other product or by-product of the work performed by Plaintiff for the Company and Zander. The action arises from approximately $1.2 million dollars of unpaid invoices (“Unpaid Invoices”) due and payable to the Plaintiff. The Company believes that no portion of the Unpaid Invoices are due and payable by the Company. The outcome of this legal proceeding may adversely affect the Company’s financial condition and operations and may also result in loss of control by the Company of certain intellectual property controlled by the Company.

Stockholders Equity

Stockholders Equity	6 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders Equity	NOTE 9. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as of March 31, 2020: Common stock, $ 0.0001 par value; 4, 800,000,000 shares authorized: 1,605,000,246 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 50,000 shares issued and outstanding as of March 31, 2020, 300,000,000 is designated Series A Preferred Stock of which 348,376,230 shares are outstanding as of March 31, 2020 and 300,000,000 is designated Series M Preferred Stock of which 44,000,000 shares are outstanding as of March 31, 2020. The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board. On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock"). The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

Investment Securities

Investment Securities	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Investment Securities	10. INVESTMENT SECURITIES On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc. On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124. On March 31, 2020 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: Fair Value of Intellectual Property $ 1,500 Prepaid Expenses 74,298 Due from Employee 1,071 Note Receivable 64,400 Accrued Interest Receivable 20,274 Investment Securities 593,357 Convertible Note Receivable 10,000 Accounts Payable 1,269,041 Notes Payable 500,000 Accrued Expenses Related Parties 89,529 Accrued Expenses 203,037 Enterprise Value 2,826,507 Less: Total Debt (2,061,607 ) Portion of Enterprise Value Attributable to Shareholders 764,900 Fair Value Per Share $ 0.0167 The abovementioned constitute the Company’s sole investment securities as of March 31, 2020 As of March 31, 2020: 470,588 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Gains Net Unrealized Gain or (Loss) realized during the Quarter ended March 31, 2020 $ 5,741 $ 7,858 $ 2,118 $ 0 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Loss Net Unrealized Gain or (Loss) realized during the Quarter ended March 31, 2020 $ 13,124 $ 12,109 $ (1,104) $ 0

Stock Transactions

Stock Transactions	6 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stock Transactions	NOTE 11. STOCK TRANSACTIONS Issuance of Common Shares: On January 2, 2020 the Company issued 69,685,185 common shares in satisfaction of $3,763 of convertible indebtedness. On January 2, 2020 the Company issued 70,793,000 common shares in satisfaction of $1,104 of convertible indebtedness , 524 of accrued interest on convertible indebtedness and $500 in fees. On January 23, 2020 the Company issued 42,035,947 common shares in satisfaction of $202 of convertible indebtedness , $558 of accrued interest on convertible indebtedness and $500 in fees.

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12. SUBSEQUENT EVENTS On May 12, 2020 the Company issued 5,238,875 Series A Preferred shares in satisfaction of $3,000 of convertible indebtedness and $1,426 of accrued interest on convertible indebtedness. On July 1, 2020 the Company issued 11,603,784 Series A Preferred shares in satisfaction of $5,000 of convertible indebtedness and $2,542 of accrued interest on convertible indebtedness. On August 7, 2020 the Company issued 16,549,800 Series A Preferred shares in satisfaction of $7,000 of convertible indebtedness and $3,757 of accrued interest on convertible indebtedness. On October 28, 2020 the Company issued 80,065,846 common shares in satisfaction of $3,752 of convertible indebtedness and $1,452 of accrued interest on convertible indebtedness. On November 6, 2020 the Company issued 83,934,153 common shares in satisfaction of $3,900 of convertible indebtedness and $1,555 of accrued interest on convertible indebtedness. On December 11, 2020 the Company issued 87,020,000 common shares in satisfaction of $7,300 of convertible indebtedness and $3,142 of accrued interest on convertible indebtedness. On December 16, 2020 the Company issued 6,437,153 common shares in satisfaction of $852 of convertible indebtedness , $429 of accrued interest on convertible indebtedness and $160 in fees.. On December 16, 2020 the Company issued 88,158,923 common shares in satisfaction of $4,030 of convertible indebtedness and $1,700 of accrued interest on convertible indebtedness. On December 17, 2020 the Company issued 83,216,917 common shares in satisfaction of $8,200 of convertible indebtedness and $1,786 of accrued interest on convertible indebtedness. On December 23, 2020 the Company issued 108,444,444 common shares in satisfaction of $16,000 of convertible indebtedness and $3,250 of accrued interest on convertible indebtedness. On December 31, 2020 the Company issued 117,837,384 common shares in satisfaction of $5,330 of convertible indebtedness and $2,329 of accrued interest on convertible indebtedness. On January 28, 2021 the Company issued 85,900,000 common shares in satisfaction of $5,154 of convertible indebtedness. On February 23, 2021 the Company issued 88,000,000 common shares in satisfaction of $4,400 of accrued interest on convertible indebtedness. On February 24, 2021 the Company issued 82,759,286 common shares in satisfaction of $30,000 of convertible indebtedness and $4,758 of accrued interest on convertible indebtedness. On March 2, 2021 the Company issued 119,269,538 common shares in satisfaction of $5,260 of convertible indebtedness and $2,492 of accrued interest on convertible indebtedness. On March 18, 2021 the Company issued 70,000,000 common shares in satisfaction of $3,415 of convertible indebtedness and $84 of accrued interest on convertible indebtedness. On March 31, 2021 the Company issued 40,000,000 common shares in satisfaction of $1926 of convertible indebtedness and $74 of accrued interest on convertible indebtedness. On April 12, 2021 the Company issued 85,000,000 common shares in satisfaction of $3111 of convertible indebtedness and $49 of accrued interest on convertible indebtedness. On April 13, 2021 the Company issued 83,636,833 common shares in satisfaction of $3,511 of convertible indebtedness and $1508 of accrued interest on convertible indebtedness. On April 13, 2021 the Company issued 10,000 Series NC Preferred shares to its Chief Executive Officer as consideration for services. On April 13, 2021 the Company issued 32,968,042 common shares in satisfaction of $19,000 of convertible indebtedness and $4736 of accrued interest on convertible indebtedness. On April 15, 2021 the Company issued 146,452,000 common shares in satisfaction of $1,416 of convertible indebtedness and $680 of accrued interest on convertible indebtedness. On April 15, 2021 the Company issued 49482000 common shares in satisfaction of $2288 of convertible indebtedness and $680 of accrued interest on convertible indebtedness. On April 16, 2021 the Company issued 70,755,885 common shares in satisfaction of $47,000 of convertible indebtedness and $8,189 of accrued interest on convertible indebtedness. On April 16, 2021 the Company issued 90,311,411 common shares in satisfaction of $4,238 of convertible indebtedness and $17 of accrued interest on convertible indebtedness. On April 21, 2021 the Company issued 163,814,000 common shares in satisfaction of $7564 of convertible indebtedness and $2,264 of accrued interest on convertible indebtedness. On April 28, 2021 the Company issued 28,784,167 common shares in satisfaction of $22,000 of convertible indebtedness and $3,905 of accrued interest on convertible indebtedness. On May 3, 2021 the Company issued 33,012,555 common shares in satisfaction of $1,416 of convertible indebtedness and $729 of accrued interest on convertible indebtedness. On May 5, 2021 the Company issued 27,753,016 common shares in satisfaction of $1,187 of convertible indebtedness and $616 of accrued interest on convertible indebtedness. On December 17, 2020 the Company issued 32,379,169 Series A Preferred shares in satisfaction of $13,000 of convertible indebtedness and $8,046 of accrued interest on convertible indebtedness. Certificate of Designations On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as "Series NC Preferred Stock"). The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 500,000. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31,2020 utilized the following inputs: Risk Free Interest Rate 1.75 % Expected Term – 0.41 Yrs Expected Volatility 273 – 312. % Expected Dividends
INCOME TAXES	C. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2020 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	D. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	E. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended March 31, 2020 and 2019.
NOTES RECEIVABLE	F. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any.
REVENUE RECOGNITION	G. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.
INTEREST RECEIVABLE	H. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Schedule of Derivative Liability	The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of March 31,2020 utilized the following inputs: Risk Free Interest Rate 1.75 % Expected Term – 0.41 Yrs Expected Volatility 273 – 312. % Expected Dividends

Notes Payable, Related Party (T

Notes Payable, Related Party (Tables)	6 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Notes Payable Related Party	As of March 31, 2020 David Koos $ 227 BST Partners 61,900 Total: $ 62,127

Investment Securities (Tables)

Investment Securities (Tables)	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Dividend Income	On March 31, 2020 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: Fair Value of Intellectual Property $ 1,500 Prepaid Expenses 74,298 Due from Employee 1,071 Note Receivable 64,400 Accrued Interest Receivable 20,274 Investment Securities 593,357 Convertible Note Receivable 10,000 Accounts Payable 1,269,041 Notes Payable 500,000 Accrued Expenses Related Parties 89,529 Accrued Expenses 203,037 Enterprise Value 2,826,507 Less: Total Debt (2,061,607 ) Portion of Enterprise Value Attributable to Shareholders 764,900 Fair Value Per Share $ 0.0167
Comprehensive Income	As of March 31, 2020: 470,588 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Gains Net Unrealized Gain or (Loss) realized during the Quarter ended March 31, 2020 $ 5,741 $ 7,858 $ 2,118 $ 0 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Loss Net Unrealized Gain or (Loss) realized during the Quarter ended March 31, 2020 $ 13,124 $ 12,109 $ (1,104) $ 0

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies (Details)	6 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Risk Free Interest Rate	1.75%
Expected Term	4 months 28 days
Expected Volatility, Minimum	273.00%
Expected Volatility, Maximum	312.00%
Expected Dividends	0.00%

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accounting Policies [Abstract]
Advertising expenses	$ 0	$ 0
Valuation allowance	100.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative)	89 Months Ended
	Mar. 31, 2020USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception	$ (20,992,464)

Notes Payable, Related Party (D

Notes Payable, Related Party (Details)	Mar. 31, 2020USD ($)
Notes Payable	$ 62,127
David Koos
Notes Payable	227
BST Partners
Notes Payable	$ 61,900

Notes Payable, Related Party _2

Notes Payable, Related Party (Details Narrative) - USD ($)	Jan. 10, 2020	Jan. 02, 2020	Dec. 02, 2019	Nov. 08, 2019	Nov. 06, 2019	Oct. 04, 2019	Oct. 02, 2019	Jan. 16, 2020	Dec. 17, 2019	Nov. 26, 2019	Nov. 15, 2019	Oct. 31, 2019	Oct. 25, 2019	Oct. 24, 2019	Sep. 30, 2020
David Koos [Member]
Note payable															$ 227
Interest rate per annum															15.00%
BST Partners
Loan	$ 2,500	$ 1,400	$ 1,000	$ 6,000	$ 1,500	$ 2,300	$ 6,000	$ 1,400	$ 1,300	$ 2,100	$ 2,000	$ 2,000	$ 1,000	$ 7,400
Interest rate	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%
Due date	Jan. 10, 2021	Jan. 2, 2021	Dec. 2, 2020	Nov. 8, 2020	Nov. 6, 2020	Oct. 4, 2020	Oct. 2, 2020	Jan. 16, 2021	Dec. 18, 2020	Nov. 26, 2020	Nov. 15, 2020	Oct. 31, 2020	Oct. 25, 2020	Oct. 24, 2020

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	6 Months Ended
	Mar. 31, 2020USD ($)
Convertible Note; December 22, 2016
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	40,000
Cash issued for convertible note	40,000
Convertible Note; March 8, 2016
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	8.00%
Maturity Date	Mar. 8, 2019
Beneficial conversion feature	$ 42,600
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	100,000
Cash issued for convertible note	100,000
Convertible Note; April 6, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	8.00%
Maturity Date	Apr. 6, 2019
Beneficial conversion feature	$ 9,900
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note; September 8, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 8, 2017
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note; September 20, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 20, 2017
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note #2; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note #3; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	$ 50,000
Convertible Note; December 22, 2016
Maturity Date	Dec. 22, 2017
Beneficial conversion feature	$ 40,000
Converted value that exceeds the principal amount	0
Convertible Note; March 1, 2017
Convertible note issued and outstanding	$ 75,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 1, 2020
Unamortized discount	$ 5,200
Outstanding balance	75,000
Derivative Liability	300,000
Cash issued for convertible note	75,000
Convertible Note; March 9, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 9, 2020
Unamortized discount	$ 0
Outstanding balance	25,000
Derivative Liability	100,000
Cash issued for convertible note	25,000
Convertible Note; March 13, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 24, 2020
Unamortized discount	$ 0
Outstanding balance	50,000
Derivative Liability	200,000
Cash issued for convertible note	25,000
Convertible Note: March 31, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 31, 2020
Unamortized discount	$ 0
Outstanding balance	50,000
Derivative Liability	200,000
Cash issued for convertible note	50,000
Convertible Note; April 19, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Apr. 19, 2020
Unamortized discount	$ 524
Outstanding balance	25,000
Derivative Liability	100,000
Cash issued for convertible note	25,000
Convertible Note #2; April 19, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Apr. 19, 2020
Unamortized discount	$ 1,049
Outstanding balance	50,000
Derivative Liability	200,000
Cash issued for convertible note	50,000
Convertible Note; May 5, 2017
Convertible note issued and outstanding	$ 200,000
Convertible note, interest rate	10.00%
Maturity Date	May 5, 2020
Unamortized discount	$ 7,116
Outstanding balance	200,000
Derivative Liability	800,000
Cash issued for convertible note	200,000
Convertible Note; May 10, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	May 9, 2020
Unamortized discount	$ 2,009
Outstanding balance	100,000
Derivative Liability	400,000
Cash issued for convertible note	100,000
Convertible Note; May 19, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	May 19, 2020
Unamortized discount	$ 1,049
Outstanding balance	50,000
Derivative Liability	200,000
Cash issued for convertible note	50,000
Convertible Note; June 26, 2017
Convertible note issued and outstanding	$ 150,000
Convertible note, interest rate	10.00%
Maturity Date	Jun. 16, 2020
Unamortized discount	$ 11,187
Outstanding balance	150,000
Derivative Liability	600,000
Cash issued for convertible note	150,000
Convertible Note; July 24, 2017
Convertible note issued and outstanding	$ 60,000
Convertible note, interest rate	10.00%
Maturity Date	Jul. 24, 2020
Unamortized discount	$ 6,459
Outstanding balance	60,000
Derivative Liability	240,000
Cash issued for convertible note	60,000
Convertible Note; September 7, 2017
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	8.00%
Maturity Date	Sep. 7, 2018
Unamortized discount	$ 0
Outstanding balance	7,000
Derivative Liability	1,723
Cash issued for convertible note	38,000
Convertible Note; August 29, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Aug. 29, 2020
Unamortized discount	$ 3,512
Outstanding balance	25,000
Derivative Liability	100,000
Cash issued for convertible note	25,000
Convertible Note; September 22, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 21, 2020
Unamortized discount	$ 8,082
Outstanding balance	50,000
Derivative Liability	200,000
Cash issued for convertible note	50,000
Convertible Note; #2 September 22, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 22, 2020
Unamortized discount	$ 16,240
Outstanding balance	100,000
Derivative Liability	400,000
Cash issued for convertible note	100,000
Convertible Note; September 25, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 25, 2020
Unamortized discount	$ 8,257
Outstanding balance	50,000
Derivative Liability	200,000
Cash issued for convertible note	50,000
Convertible Note; October 3, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 3, 2020
Unamortized discount	$ 9,397
Outstanding balance	50,000
Derivative Liability	200,000
Cash issued for convertible note	50,000
Convertible Note; October 4, 2017
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 4, 2020
Unamortized discount	$ 7,554
Outstanding balance	40,000
Derivative Liability	160,000
Cash issued for convertible note	40,000
Convertible Note; October 16, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 9, 2020
Unamortized discount	$ 19,981
Outstanding balance	100,000
Derivative Liability	400,000
Cash issued for convertible note	100,000
Convertible Note; November 01, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Nov. 1, 2020
Unamortized discount	$ 5,360
Outstanding balance	25,000
Derivative Liability	100,000
Cash issued for convertible note	25,000
Convertible Note; #2 November 1, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Nov. 1, 2020
Unamortized discount	$ 0
Outstanding balance	25,000
Derivative Liability	100,000
Cash issued for convertible note	25,000
Convertible Note; December 15, 2017
Convertible note issued and outstanding	$ 35,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 15, 2020
Unamortized discount	$ 8,909
Outstanding balance	35,000
Derivative Liability	140,000
Cash issued for convertible note	35,000
Convertible Note; December 20, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 20, 2020
Unamortized discount	$ 25,912
Outstanding balance	100,000
Derivative Liability	400,000
Cash issued for convertible note	100,000
Convertible Note #2; December 20, 2017
Convertible note issued and outstanding	$ 115,000
Convertible note, interest rate	8.00%
Maturity Date	Dec. 6, 2018
Unamortized discount	$ 0
Outstanding balance	31,893
Derivative Liability	49,066
Cash issued for convertible note	100,000
Original Issue Discount	1,750
Convertible Note; December 06, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 6, 2020
Unamortized discount	$ 12,317
Outstanding balance	50,000
Derivative Liability	200,000
Cash issued for convertible note	50,000
Convertible Note; January 24, 2018
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 6, 2020
Unamortized discount	$ 6,232
Outstanding balance	25,000
Derivative Liability	100,000
Cash issued for convertible note	25,000
Convertible Note; February 28, 2018
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 28, 2021
Unamortized discount	$ 31,478
Outstanding balance	100,000
Derivative Liability	400,000
Cash issued for convertible note	$ 100,000
Convertible Note; February 26, 2018
Maturity Date	Feb. 26, 2019
Convertible Note; May 18, 2018
Convertible note issued and outstanding	$ 114,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 18, 2019
Unamortized discount	$ 0
Outstanding balance	65,149
Derivative Liability	108,582
Cash issued for convertible note	100,000
Original Issue Discount	14,000
Convertible Note; July 11, 2018
Convertible note issued and outstanding	$ 11,500
Convertible note, interest rate	10.00%
Maturity Date	May 4, 2021
Unamortized discount	$ 4,485
Outstanding balance	11,500
Derivative Liability	46,000
Cash issued for convertible note	$ 11,500
Convertible Note; August 14, 2018
Maturity Date	Aug. 13, 2019
Convertible Note; September 30, 2018
Convertible note issued and outstanding	$ 350,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 30, 2020
Beneficial conversion feature	$ 350,000
Unamortized discount	5,952
Converted value that exceeds the principal amount	28,888
Outstanding balance	10,000
Derivative Liability	350,000
Cash issued for convertible note	350,000
Convertible Note; October 3, 2018
Convertible note issued and outstanding	$ 63,000
Convertible note, interest rate	8.00%
Maturity Date	Oct. 3, 2019
Unamortized discount	$ 0
Outstanding balance	33,560
Derivative Liability	51,630
Cash issued for convertible note	60,000
Convertible Note; October 10, 2018
Convertible note issued and outstanding	$ 75,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 11, 2019
Unamortized discount	$ 0
Outstanding balance	50,500
Derivative Liability	77,692
Cash issued for convertible note	71,250
Convertible Note; January 22, 2019
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Jan. 22, 2020
Unamortized discount	$ 3,424
Outstanding balance	19,607
Derivative Liability	32,678
Cash issued for convertible note	47,500
Convertible Note; July 19, 2019
Convertible note issued and outstanding	$ 100,000
Maturity Date	Jul. 19, 2020
Unamortized discount	$ 30,327
Outstanding balance	100,000
Derivative Liability	166,666
Cash issued for convertible note	95,000
Convertible Note #2; July 19, 2019
Convertible note issued and outstanding	$ 20,331
Maturity Date	Jul. 19, 2019
Unamortized discount	$ 6,167
Outstanding balance	20,331
Derivative Liability	31,278
Cash issued for convertible note	18,831
Convertible Note #3; July 19, 2019
Convertible note issued and outstanding	$ 14,819
Maturity Date	Jul. 19, 2019
Unamortized discount	$ 7,420
Outstanding balance	14,819
Derivative Liability	24,698
Cash issued for convertible note	13,319
Convertible Note; February 15, 2019
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	60.00%
Unamortized discount	$ 0
Outstanding balance	19,018
Derivative Liability	31,696
Cash issued for convertible note	$ 47,500

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	6 Months Ended
	Mar. 31, 2020USD ($)
Notes Payable, Total amount	$ 62,127
BST Partners
Notes Payable, Total amount	61,900
David Koos
Notes Payable, Total amount	227
Note payable	227
Convertible Note; September 30, 2018
Convertible note issued and outstanding	$ 350,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 30, 2020
Outstanding balance	$ 10,000
Convertible Note; July 11, 2018
Convertible note issued and outstanding	$ 11,500
Convertible note, interest rate	10.00%
Maturity Date	May 4, 2021
Outstanding balance	$ 11,500

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - $ / shares	6 Months Ended
	Mar. 31, 2020	Sep. 30, 2019
Common stock, Par value	$ 0.0001	$ 0.0001
Common stock, authorized	4,800,000,000	4,800,000,000
Common stock issued and outstanding	160,500,246	600,001,406
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	800,000,000	800,000,000
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	600,000	600,000
Preferred stock, shares issued and outstanding	50,000	50,000
Preferred stock, shares outstanding	50,000	50,000
Preferred shares voting	Series AA Preferred Stock
Series M
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	300,000,000	300,000,000
Preferred stock, shares issued and outstanding	44,000,000	38,000,000
Preferred stock, shares outstanding	44,000,000	38,000,000
Preferred shares voting	On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock").
Series A
Preferred stock, non-cumulative cash dividends	$ 0.01
Preferred shares voting	Series A Preferred Stock
Series A Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	300,000,000	300,000,000
Preferred stock, shares issued and outstanding	348,376,230	348,376,230
Preferred stock, shares outstanding	348,376,230	348,376,230

Investment Securities (Details)

Investment Securities (Details) - USD ($)	Mar. 31, 2020	Sep. 30, 2019
Prepaid Expenses	$ 40	$ 76
Accounts Payable	107,430	$ 92,000
Series M | Zander Therapeutics
Fair Value of Intellectual Property	1,500
Prepaid Expenses	74,298
Due from Employee	1,071
Note Receivable	64,400
Accrued Interest Receivable	20,274
Investment Securities	593,357
Convertible Note Receivable	10,000
Accounts Payable	1,269,041
Notes Payable	500,000
Accrued Expenses, Related Party	89,529
Accrued Expenses	203,037
Enterprise Value	2,826,507
Less: Total Debt	(2,061,607)
Portion of Enterprise Value attributable to Shareholders	$ 764,900
Fair Value per share	$ 0.0167
Common Stock | Zander Therapeutics
Fair Value of Intellectual Property	$ 1,500
Prepaid Expenses	74,298
Due from Employee	1,071
Note Receivable	64,400
Accrued Interest Receivable	20,274
Investment Securities	593,357
Convertible Note Receivable	10,000
Accounts Payable	1,269,041
Notes Payable	500,000
Accrued Expenses, Related Party	89,529
Accrued Expenses	203,037
Enterprise Value	2,826,507
Less: Total Debt	(2,061,607)
Portion of Enterprise Value attributable to Shareholders	$ 764,900
Fair Value per share	$ 0.0167

Investment Securities (Details

Investment Securities (Details 1) - USD ($)	6 Months Ended
	Mar. 31, 2020	Sep. 30, 2019
Investment Securities, Fair Value	$ 19,969	$ 19,969
Common Stock | Zander Therapeutics
Investment Securities, Basis	5,741
Investment Securities, Fair Value	7,858
Investment Securities, Total Unrealized Gain	2,118
Investment Securities, net Unrealized Gain or (Loss) realized	0
Series M | Zander Therapeutics
Investment Securities, Basis	13,124
Investment Securities, Fair Value	12,109
Investment Securities, Total Unrealized Gain	(1,104)
Investment Securities, net Unrealized Gain or (Loss) realized	$ 0

Investment Securities (Detail_2

Investment Securities (Details Narrative) - Zander Therapeutics - USD ($)	Jun. 11, 2018	Nov. 29, 2018	Mar. 31, 2020
Number of shares issued for property dividend	470,588		470,588
Series M
Number of shares issued in satisfaction of prepaid rent and accrued interest		725,000	725,000
Shares issued in satisfaction of prepaid rent and accrued interest, value		$ 13,124

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - Convertible Debt - Common Stock - USD ($)	Jan. 02, 2020	Jan. 02, 2020	Jan. 23, 2020
Shares issued in satisfaction of convertible identedness	70,793,000	69,685,185	42,035,947
Value of shares issued in satisdaction of convertible debt	$ 1,104	$ 3,763	$ 202
Accrued Interest	524		558
Fees	$ 500		$ 500

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 05, 2021	May 03, 2021	Apr. 15, 2021	Apr. 13, 2021	Apr. 13, 2021	Apr. 12, 2021	Mar. 02, 2021	Dec. 16, 2020	Dec. 16, 2020	Dec. 11, 2020	Nov. 06, 2020	Aug. 07, 2020	Jul. 01, 2020	May 12, 2020	Jan. 02, 2020	Jan. 02, 2020	Apr. 28, 2021	Apr. 21, 2021	Apr. 16, 2021	Apr. 16, 2021	Apr. 15, 2021	Mar. 31, 2021	Mar. 26, 2021	Mar. 18, 2021	Feb. 24, 2021	Feb. 23, 2021	Jan. 28, 2021	Dec. 31, 2020	Dec. 23, 2020	Dec. 17, 2020	Dec. 17, 2020	Oct. 28, 2020	Jan. 23, 2020	Mar. 31, 2020	Sep. 30, 2019
Common stock, Par value																																		$ 0.0001	$ 0.0001
Common stock, authorized																																		4,800,000,000	4,800,000,000
Convertible Debt | Common Stock
Shares issued in satisfaction of convertible identedness															70,793,000	69,685,185																	42,035,947
Value of shares issued in satisdaction of convertible debt															$ 1,104	$ 3,763																	$ 202
Accrued Interest															$ 524																		$ 558
Subsequent Event [Member] | Series NC Preferred Stock
Stock issued for services					10,000
Subsequent Event [Member] | Convertible Debt | Series NC Preferred Stock
Common stock, Par value																							$ 0.0001
Common stock, authorized																							20,000
Number of non voting convertible preferred stock sold																							500,000
Subsequent Event [Member] | Convertible Debt | Series A Preferred Stock
Shares issued in satisfaction of convertible identedness												16,549,800	11,603,784	5,238,875																	32,379,169
Value of shares issued in satisdaction of convertible debt												$ 7,000	$ 5,000	$ 3,000																	$ 13,000
Accrued Interest												$ 3,757	$ 2,542	$ 1,426																	$ 8,046
Subsequent Event [Member] | Convertible Debt | Common Stock
Shares issued in satisfaction of convertible identedness	27,753,016	33,012,555	49,482,000	83,636,833	32,968,042	85,000,000	119,269,538	6,437,153	88,158,923	87,020,000	83,934,153						28,784,167	163,814,000	70,755,885	90,311,411	146,452,000	40,000,000		70,000,000	82,759,286	88,000,000	85,900,000	117,837,384	108,444,444	83,216,917		80,065,846
Value of shares issued in satisdaction of convertible debt	$ 1,187	$ 1,416	$ 2,288	$ 3,511	$ 19,000	$ 3,111	$ 5,260	$ 852	$ 4,030	$ 7,300	$ 3,900						$ 22,000	$ 7,564	$ 47,000	$ 4,238	$ 1,416	$ 1,926		$ 3,415	$ 30,000	$ 4,400	$ 5,154	$ 5,330	$ 16,000	$ 8,200		$ 3,752
Accrued Interest	$ 616	$ 729	$ 680	$ 1,508	$ 4,736	$ 49	$ 2,492	$ 429	$ 1,700	$ 3,142	$ 1,555						$ 3,905	$ 2,264	$ 8,189	$ 17	$ 680	$ 74		$ 84	$ 4,758			$ 2,329	$ 3,250	$ 1,786		$ 1,452